do-2
Adult Solid Tumor
DeuterOncologyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the Adult Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab CatalYm GmbH | Phase 2 | BB |
Docetaxel CatalYm GmbH | Phase 3 | B |
Nivolumab CatalYm GmbH | Phase 2 | B |
Crofelemer Napo Pharmaceuticals, Inc. | Phase 3 | B |
Durvalumab Institut Bergonié | Phase 2 | B |
View all 31 →
Same molecule, other indications
do-2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →